Hrt Financial LP Mannkind Corp Transaction History

Hrt Financial LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$3.91 - $5.45 $58,102 - $80,987	14,860 Added 6.95%	228,558 $943,000
Q2 2023 Aug 11, 2023	BUY	$3.72 - $4.79 $794,956 - $1.02 Million	213,698 New	213,698 $869,000
Q4 2022 Feb 10, 2023	BUY	$3.02 - $5.37 $1.76 Million - $3.13 Million	582,647 New	582,647 $3.07 Million
Q2 2022 Aug 12, 2022	BUY	$2.67 - $4.77 $1.13 Million - $2.01 Million	422,270 New	422,270 $1.61 Million
Q1 2022 May 16, 2022	SELL	$2.62 - $4.45 $437,802 - $743,595	-167,100 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $576,509 - $764,408	142,348 Added 575.1%	167,100 $730,000
Q3 2021 Nov 15, 2021	BUY	$3.89 - $5.48 $96,285 - $135,640	24,752 New	24,752 $107,000
Q1 2018 May 14, 2018	SELL	$2.28 - $3.8 $53,548 - $89,246	-23,486 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$2.28 - $6.71 $53,548 - $157,591	23,486	23,486 $54,000

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.81B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.